Treatment with anti-CSF1R depletes only TAMs with an inflammatory gene signature but not PMN-MDSCs in colorectal cancer patients, leading to cancer-promoting effects through the accumulation of tumor-infiltrating PMN-MDSCs, which aggregated in tumors. This evidence concerns the gene CSF1R and neoplasm.